An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest that responsiveness of advanced male breast cancer to systemic chemotherapeutic agents is the same as that reported for advanced female breast cancer.
(JAMA 243:1739-1741, 1980)
Yap H, Tashima CK, Blumenschein GR, Hortobagyi GN, Eckles N. Chemotherapy for Advanced Male Breast Cancer. JAMA. 1980;243(17):1739–1741. doi:10.1001/jama.1980.03300430041021
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: